Journal Article

Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis

Michael B. Stokes, Kirk Foster, Glen S. Markowitz, Farhang Ebrahimi, William Hines, Darren Kaufman, Brooke Moore, Daniel Wolde and Vivette D. D'Agati

in Nephrology Dialysis Transplantation

Published on behalf of European Renal Association - European Dialysis and Transplant Assoc

Volume 20, issue 7, pages 1400-1406
Published in print July 2005 | ISSN: 0931-0509
Published online April 2005 | e-ISSN: 1460-2385 | DOI:
Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis

Show Summary Details


Background. Treatment of rheumatoid arthritis with anti-tumour necrosis factor alpha (TNFα) agents may lead to autoantibody formation and flares of vasculitis, but renal complications are rare.

Methods. We report the clinical and pathologic findings in five patients with longstanding rheumatoid arthritis (duration of rheumatoid arthritis, 10–30 years; mean, 23 years) who developed new onset of glomerular disease after commencing therapy with anti-TNFα agents (duration of therapy, 3–30 months; median, 6 months).

Results. At presentation, three patients were receiving etanercept, one adalimumab and one infliximab. Two subjects presented with acute renal insufficiency, haematuria, nephrotic-range proteinuria, positive lupus serologies, and hypocomplementemia, and renal biopsies showed proliferative lupus nephritis. Two individuals presented with new onset renal insufficiency, haematuria and proteinuria, and renal biopsies showed pauci-immune necrotizing and crescentic glomerulonephritis. One of these subjects, who had anti-myeloperoxidase autoantibodies, also developed pulmonary vasculitis. The fifth patient presented with nephrotic syndrome and renal biopsy findings of membranous glomerulonephritis, associated with immune complex renal vasculitis. A pathogenic role for anti-TNFα therapy is suggested by the close temporal relationship with development of glomerular disease, and by the improvement in clinical and laboratory abnormalities after drug withdrawal and initiation of immunosuppressive therapy in most cases.

Conclusions. Rheumatoid arthritis patients receiving anti-TNFα agents may develop glomerulonephritis via the induction of rheumatoid arthritis-related nephropathy or de novo autoimmune disorders.

Keywords: adalimumab; etanercept; glomerulonephritis; infliximab; lupus; TNFα

Journal Article.  4344 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.